GlassScriptPhysician profile
Drew Scoles
NPI 1902260698
$518.99
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2020: $49.29 · 2021: $65.02 · 2022: $300.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $122.90 | 2019-2021 | |
| Genentech USA, INC. | $120.83 | 2022 | |
| Eyepoint US, INC. | $96.04 | 2020-2021 | |
| Biogen, INC. | $79.80 | 2022 | |
| Regeneron Pharmaceuticals, INC. | $75.83 | 2022 | |
| Bausch & Lomb Americas INC. | $23.59 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Drew Scoles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.